ストックスクリーナーアプリを入手
7.99
0.62%
-0.05
プレマーケット:
8.07
0.08
+1.00%
前日終値:
$8.04
開ける：
$8
24時間の取引高:
256.33K
Relative Volume:
0.73
時価総額：
$183.96M
収益：
-
当期純損益:
$-52.07M
株価収益率:
-38.47
EPS:
-0.2077
ネットキャッシュフロー:
$-44.93M
1週間 パフォーマンス:
-3.97%
1か月 パフォーマンス:
-3.27%
6か月 パフォーマンス:
-20.34%
1年 パフォーマンス:
-26.33%
1日の値動き範囲:
$7.80
$8.0699
1週間の範囲:
$7.55
$8.84
52週間の値動き範囲:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
CYBN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.99 | 185.19M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Guggenheim | Buy |
| 2021-11-19 | ダウングレード | Maxim Group | Buy → Hold |
Cybin Inc (CYBN) 最新ニュース
What are analysts’ price targets for Cybin Inc. in the next 12 monthsInvest confidently with real-time data analysis - jammulinksnews.com
Why is Cybin Inc. stock attracting strong analyst attentionMaximize your portfolio’s growth potential - jammulinksnews.com
When is Cybin Inc. stock expected to show significant growthPre Market Trend Scanner With High Returns - jammulinksnews.com
What are Cybin Inc. company’s key revenue driversAchieve rapid wealth accumulation through smart investing - jammulinksnews.com
Is Cybin Inc. stock overvalued or undervaluedConsistently superior profits - jammulinksnews.com
What institutional investors are buying Cybin Inc. stockAchieve consistent returns with proven methods - jammulinksnews.com
What are the technical indicators suggesting about Cybin Inc.Access high-yield investment alerts now - jammulinksnews.com
What is the dividend policy of Cybin Inc. stockInvest smarter with daily market updates - jammulinksnews.com
Should I hold or sell Cybin Inc. stock in 2025Extraordinary performance - jammulinksnews.com
How Cybin Inc. stock performs during market volatilitySolid Return Trade Selections - metal.it
What analysts say about Cybin Inc. stockSuperior portfolio returns - PrintWeekIndia
Cybin Inc. Stock Analysis and ForecastFree Capital Efficiency Planning - PrintWeekIndia
Is Cybin Inc. a good long term investmentExceptional growth trajectory - PrintWeekIndia
Cybin, Inc: CYB003 Vs. GH001Duration, Durability and Protocol Execution - Smartkarma
What drives Cybin Inc. stock pricePowerful market insights - PrintWeekIndia
Will Cybin Inc. stock benefit from AI tech trendsFree Predictions - jammulinksnews.com
I can have 5% loss. - AInvest
(CYBN) Proactive Strategies - news.stocktradersdaily.com
High-Risk, High-Reward Stocks With Serious Momentum: 5 Stocks to Consider - AInvest
Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan - Smartkarma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - Yahoo Finance
UK MHRA approves Cybin’s trial of CYB003 for major depressive disorder - Yahoo Finance
Three High-Risk, High-Reward Stocks in AI, Biotech, and Autonomous Vehicles - AInvest
Cybin's EMBRACE Study: A Pivotal Step in Psychedelic-Driven Mental Healthcare Innovation - AInvest
Cybin receives UK MHRA approval to commence EMBRACE study - TipRanks
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Cybin Secures UK Approval for Pivotal Depression Study - TipRanks
Cybin receives UK approval for second pivotal depression study By Investing.com - Investing.com South Africa
Cybin receives UK approval for second pivotal depression study - Investing.com
Cybin Inc (CYBN) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):